Synapse - Mark Kris

Results (168)

Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers

Meeting Abstract

Kris, M. G.; Offin, M. D.; Feldman, D. L.; Ni, A.; Lai, W. C. V.; Arbour, K. C.; Daras, M.; Pentsova, E.; DeAngelis, L. M.; Beal, K.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Molecular and imaging predictors of response to ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: An exploratory phase 2 trial

Meeting Abstract

Li, B.; Offin, M.; Hembrough, T.; Cecchi, F.; Shen, R.; Olah, Z.; Panora, E.; Myers, M.; Brzostowski, E.; Buonocore, D.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

MET exon 14-altered lung cancers: Central nervous system (CNS) metastases and patterns of CNS progression on MET inhibition

Meeting Abstract

Offin, M.; Dienstag, J.; Wilkins, O.; Sabari, J.; Ni, A.; Feldman, D.; Van Voorthuysen, M.; Suzawa, K.; Yu, H.; Riely, G.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

Clinical and molecular characteristics of EGFR mutant lung cancers with concurrent TP53 and RB1 mutations

Meeting Abstract

Offin, M.; Tenet, M.; Shen, R.; Rekhtman, N.; Rizvi, H.; Hellmann, M.; Arcila, M.; Ladanyi, M.; Rudin, C.; Kris, M.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Journal Article

Sabari, J. K.; Leonardi, G. C.; Shu, C. A.; Umeton, R.; Montecalvo, J.; Ni, A.; Chen, R.; Dienstag, J.; Mrad, C.; Bergagnini, I.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial

Journal Article

Li, B. T.; Shen, R. L.; Buonocore, D.; Olah, Z. T.; Ni, A.; Ginsberg, M. S.; Ulaner, G. A.; Offin, M.; Feldman, D.; Hembrough, T.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET–rearranged lung cancers

Journal Article

Drilon, A.; Lin, J. J.; Filleron, T.; Ni, A.; Milia, J.; Bergagnini, I.; Hatzoglou, V.; Velcheti, V.; Offin, M.; Li, B.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC

Journal Article

Santini, F. C.; Rizvi, H.; Plodkowski, A. J.; Ni, A.; Lacouture, M. E.; Gambarin-Gelwan, M.; Wilkins, O.; Panora, E.; Halpenny, D. F.; Long, N. M.; more...
Cancer Immunology Research (2018)

Fulltext@MSK | Save

Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance

Journal Article

Yu, H. A.; Suzawa, K.; Jordan, E.; Zehir, A.; Ni, A.; Kim, R.; Kris, M. G.; Hellmann, M. D.; Li, B. T.; Somwar, R.; more...
Clinical Cancer Research (2018)

Fulltext@MSK | Save

Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing

Journal Article

Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J. L.; Rekhtman, N.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save